Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Enasidenib

Research Leaders

6 sponsors active, led by Incyte Corporation

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT04281498Phase 2Completed

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Showing all 1 trials

Research Network

Common Treatments

  • Enasidenib1
  • Ruxolitinib1

Active Sponsors

  • Incyte Corporation1
  • John Mascarenhas1
  • National Cancer Institute (NCI)1
  • Celgene Corporation1
  • Myeloproliferative Neoplasms Research Consortium1

Top Investigators

Related Conditions

  • Idh2 Mutation1
  • Acceleratedblastphase Myeloproliferative Neoplasm1

Activity Timeline